nusinersen: latest news - GoINPHARMA
Saturday, 15 December 2018 - 22:06


CHMP: OK to Biogen’s Spinraza for SMA

Biogen has announced that EMA CHMP has adopted a positive opinion on Spinraza (nusinersen) for the treatment of SMA (spinal muscular atrophy). The Agency has reviewed the product under its accelerated assessment program, designed to facilitate access to medicines likely…

Biogen’s Spinraza, positive data in SMA

Biogen presented new data from the Phase III ENDEAR study of Spinraza (nusinersen), which demonstrated a significant reduction in the risk of death or permanent ventilation in infants with SMA (spinal muscular atrophy) treated with Spinraza vs the untreated group….